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ORIGINAL RESEARCH
Aberrant fucosylation enables breast cancer clusterin to interact with dendritic
cell-specific ICAM-grabbing non-integrin (DC-SIGN)
Antonela Merlottia,b*, Alvaro López Maliziaa*, Paula Micheab, Pierre-Emmanuel Bonteb, Christel Goudotb,
María Sol Carregala, Nicolás Nuñezb, Christine Sedlikb, Ana Ceballosa, Vassili Soumelisb, Sebastián Amigorenab,
Jorge Geffnera, Eliane Piaggiob, and Juan Sabattea
aInstituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires,
Argentina; bInstitut Curie, PSL Research University, INSERM U932, Paris, France
ABSTRACT
Clusterin is a glycoprotein able to mediate different physiological functions such as control of complement
activation, promotion of unfolded protein clearance and modulation of cell survival. Clusterin is over-
expressed in many types of cancers and a large body of evidence suggests that it promotes carcinogenesis
and tumor progression. We have previously described a novel clusterin glycoform present in human semen,
but not in serum, highly enriched in terminal fucose motifs. Here we show that human luminal breast cancer
(LBC) clusterin also bears terminal fucosylated glycans, conferring clusterin the ability to interact with DC-
SIGN, a C-type lectin receptor expressed by myeloid cells. This clusterin glycosylation pattern was absent or
diminished in non-involved juxtatumoral tissue, suggesting that fucosylated clusterin might represent
a cancer associated glycoform. We also found that DC-SIGN is expressed by luminal breast cancer intratu-
moral macrophages. Moreover, experiments performed in vitro using semen fucosylated clusterin and
monocyte derived macrophages showed that the interaction of semen clusterin with DC-SIGN promoted
a proangiogenic profile, characterized by a high production of VEGF, IL-8 and TNF-α. Our results reveal an
unexpected complexity on the structure and function of secretory clusterin produced by tumors and suggest
that fucosylated clusterin produced by luminal breast cancer cells might play a role in tumor progression by
promoting the release of pro-angiogenic factors by intratumoral macrophages.
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Clusterin is a multifunctional glycoprotein present in almost
all tissues and body fluids. It was shown to be involved in
a number of physiological and pathological processes includ-
ing apoptosis modulation, protein homeostasis, Alzheimer´s
disease and cancer progression.1
Clusterin expression is dysregulated in many types of
tumors, including colon, gastric, prostate, ovarian, bladder,
lung and breast cancer.2 Clusterin expression usually corre-
lates with bad prognostic, disease recurrence or resistance to
therapy.3–6 Intriguingly, the nature of these associations is still
controversial. While the expression of clusterin in the cytosol
of tumor cells inhibits apoptosis promoting tumor progres-
sion and resistance to chemotherapy, nuclear clusterin seems
to induce cell death.7 In addition, clusterin is also secreted to
the extracellular milieu, however, its role on the tumor micro-
environment remains poorly understood.
Clusterin is a highly glycosylated protein with 30 percent of
its molecular mass contributed by glycans.8,9 We have pre-
viously described a novel clusterin glycoform in semen.10
Semen clusterin bears highly fucosylated LewisX and LewisY
type glycans.10 In contrast, serum clusterin is decorated by
non-fucosylated terminal sialylated glycans.8,10 Lewis type
fucosylated glycan motifs enable semen clusterin to interact
with DC-SIGN, a C type lectin receptor expressed by myeloid
cells, preventing HIV recognition by dendritic cells.10
Moreover, we have also reported that the interaction of
semen clusterin with DC-SIGN promotes antigen capture by
dendritic cells (DCs) and DC differentiation into a tolerogenic
profile characterized by an increased ability to promote the
expansion of FOXP3+ regulatory T cells.11
A key feature of cancer is the acquisition of glycan motifs
different than those expressed by healthy tissues, a phenomenon
often referred as “aberrant glycosylation”.12,13 The expression of
fucosylated Lewis type motifs is one of the most common altera-
tions in the glycosylation pattern of cancer cells.14 The neo-
expression of Sialyl LewisX motifs renders neoplastic cells able to
bind endothelium selectins promoting metastasis. Intriguing,
many tumors express non-sialylated Lewis type glycans, which
are unable to bind selectins. The contribution of this glycosylation
pattern to tumor growth has not been clearly characterized.15
In the present study we show that human breast tumors
express fucosylated clusterin. Interestingly, fucosylated clusterin
was absent or diminished in juxtatumor tissues suggesting that
it might represent a cancer associated glycoform. Moreover, we
here report the expression of DC-SIGN by intratumoral macro-
phages, which represent the most prominent myeloid cell
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population infiltrating breast tumors.16 Using an in vitro
model, we show that fucosylated clusterin turns macrophages
into a pro-angiogenic profile, suggesting a novel pathway link-
ing clusterin and tumor growth.
Results
Fucosylated clusterin expression in breast cancer
We first analyzed the expression of clusterin in luminal breast
cancer samples. The patient cohort characteristics are
described in Table 1. For each patient, a fragment of tumor
and pathologically non-involved juxtatumoral tissue were
obtained. The pattern of clusterin expression was analyzed
by immunohistochemistry (Figure 1(a,b)). As described pre-
viously, clusterin is expressed in the cytoplasm of breast
cancer cells (Figure 1(a)) and shows an apical expression
pattern in normal epithelial cells (Figure 1(b)). Clusterin
expression was quantified by ELISA in disaggregated tumor
samples and their juxtatumoral counterparts. As shown in
Figure 1(c), no statistically significant differences were found
in the mean total amount of clusterin between tumoral and
juxtatumoral tissues (n = 21).
We and others have previously described a novel fucosylated
glycoform of clusterin present in semen. In contrast to serum
clusterin, semen clusterin bears abundant LewisX and LewisY
type fucosylated motifs.10,17 Because changes in the expression
status of glycan structures represent a common feature of
cancer, and considering that fucosylation of tumor glycopro-
teins appears to be associated with increased tumorigenicity,
invasiveness and metastatic ability,14,15 we speculated that
breast carcinoma might express fucosylated clusterin. To test
this hypothesis, we developed two different ELISA assays based
on the ability of the lectins Ulex europaeus and Lotus tetra-
gonolobus to bind terminal fucose motifs. The Ulex europaeus
agglutinin-1 (UEA-1) binds to LewisY as well as to other term-
inal fucosylated motifs.18 The Lotus tetragonolobus lectin binds
to LewisX and LewisY motifs.19 The characteristics of the ELISA
assay are illustrated in Figure 2(a). As shown in Figure 2(b)
(blue bars), using Ulex europaeus agglutinin-1, fucosylated
semen clusterin, but not serum clusterin or recombinant clus-
terin, was detected through this assay. As expected, α-L-fucose
Table 1. Patient sample characteristics.
Total Number of patients = 21







Invasive ductal carcinoma (IDC) 14






Estrogen receptor (ER) positive 21
Progesteron receptor (PR) positive 20
Figure 1. Clusterin expression in luminal breast cancer samples. A and B. Clusterin expression was analyzed by immunohistochemistry in tumoral (a) and
juxtatumoral (b) tissues. Representative pictures are shown (n = 3, bars: 50 µm). C. Clusterin expression was quantified in tumor samples and their juxtatumoral
counterparts by ELISA. Results are expressed as the amount of clusterin/total protein (µg of clusterin/mg of total protein, n = 21, ns = no statistically significant
differences, p = .31).
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completely abrogated semen clusterin detection (red bars).
Similar results were obtained using Lotus tetragonolobus (not
shown). Then, we analyzed the expression of fucosylated clus-
terin by breast tumoral and juxtatumoral samples. Results in
Figure 2(c,d) show that tumor samples express higher amounts
of terminal fucosylated clusterin compared with juxtatumoral
samples.
We have previously reported that the binding of seminal
plasma clusterin to DC-SIGN depends on terminal fucosy-
lated LewisX and LewisY motifs.10 The interaction of fucosy-
lated ligands with DC-SIGN was shown to promote the
acquisition of a tolerogenic profile by DCs.20–23 We hypothe-
sized that fucosylated clusterin from breast tumors might
facilitate tumor escape from immune destruction by
interacting with DC-SIGN expressed by infiltrating myeloid
cells. To test this hypothesis, we first analyzed whether fuco-
sylated clusterin from luminal breast tumors actually inter-
acted with DC-SIGN. In these experiments, 3 pairs of tumor
and juxtatumoral samples were analyzed in western blot like
assays. In this assay, the binding of clusterin to DC-SIGN is
evaluated by adding soluble DC-SIGN-huFc chimera instead
of a primary antibody. For each pair, a similar amount of total
clusterin was lo added into the gel, as shown on the upper
panel of Figure 2(e) using anti-clusterin antibodies. The lower
panel of Figure 2(e) shows that tumor clusterin, but not
clusterin from juxtatumoral tissues, effectively binds DC-
SIGN. Figure 2(f) shows the ratio between DC-SIGN-huFC
binding and total CLU. The fold change between tumor and
Figure 2. Fucosylated clusterin (fCLU) is expressed in luminal breast cancer and interacts with DC-SIGN. a. Scheme of the ELISA assay used to detect fucosylated
clusterin. Clusterin is captured by a mAb directed to clusterin and the presence of fucosylated clusterin (fCLU) is revealed by using either biotinilated Ulex europaeus
agglutinin-I lectin (UEA-I) or Lotus tetragonolobus lectin (LT). b. Fucosylated semen clusterin, but not serum or recombinant clusterin (blue bars), was detected by the
assay described in (a). The addition of α-L-fucose prevents the recognition of fucosylated semen clusterin (red bars). Results are expressed as the mean ± SD of 4
independent experiments. c and d. Fucosylated clusterin expression in breast tumor and juxtatumoral samples (n = 14–21) was analyzed using Lotus tetragonolobus
lectin (c) or Ulex europaeus agglutinin-I (d). Results are expressed as the amount of fucosylated clusterin relative to the amount of total clusterin (left panels) or total
protein (right panels) (***p < .001, **p < .01, *p < .05). E. The ability of clusterin from tumor samples and juxtatumoral samples to bind to DC-SIGN was evaluated.
Upper panel: the presence of clusterin was evaluated using a mAb directed to clusterin. Lower panel: the membrane was stripped and revealed using DC-SIGN-huFc
and HRP conjugated anti-huIgG. Of note, total clusterin but not total protein was used to normalize the amount of sample loaded into the gel for each tumor and
juxtatumor sample pair. Accordingly, no loading control was analyzed. Panel F shows the ratio between DC-SIGN-huFC binding and total CLU. The fold change
between tumor and juxtatumor CLU ratios are shown.
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juxtatumor CLU ratios are shown. Overall, these observations
indicate that clusterin present in breast tumor samples bears
terminal fucosylated motifs and binds to DC-SIGN.
The synthesis of fucosylated Lewis type motifs is regulated
by the action of different fucosyltransferases (FUTs) in the
Golgy complex. To study the expression of fucosyltrans-
ferases and clusterin we analyze a cohort of breast cancer
patients previously caracherized by Chung et al, using single
cell transcriptomics.24 This study provides the transcriptome
analysis of 515 single cells from tumor samples of 11 patients
with different breast cancer subtypes. Unsupervised princi-
pal component analysis (PCA) shows extensive intratumoral
heterogeneity (Figure 3(a)). In Figure 3(b,c), tumor and
different lineages of non-tumor cells where identified using
gene expression signatures previously described.24 As shown
on Figure 3(d,e), clusterin is predominantly expressed by
tumor and stromal cells, but not by tumor infiltrating
immune cells. We then analyzed the expression of FUTs
that might be involved in clusterin fucosylation. The expres-
sion of different FUTs in breast cancer has already been
reported.25–27 The expression of FUT1, FUT2 and FUT3
was detected in tumor cells while FUT11 expression was
observed in tumor and non-tumor cells. As shown in
Figure 3(f), clusterin and FUTs are coexpressed in
a proportion of the cells. These cells are potential sources
of fucosylated clusterin in breast cancer tissues.
Analysis of DC-SIGN expression in breast cancer
We next analyzed DC-SIGN expression by the different popula-
tions of DC and macrophages found in breast tumor samples
using flow cytometry. The gating strategy is illustrated in Figure
4(a). As previously described,28 we identified four major DC
populations: CD11c− CD123+ plasmacytoid pre-DCs, CD11c+
BDCA1+ CD14− DCs, CD11c+ BDCA1− CD14− DCs, and
CD11c+ BDCA1+ CD14+ inflammatory DCs. The most promi-
nent intratumoralmyeloid cell population, however, was shown to
be represented by macrophages, defined as CD11c+ BDCA1−
CD14+ cells. We analyzed DC-SIGN expression on the surface of
these populations by flow cytometry. As shown on Figure 4(c),
DC-SIGN was only expressed on the membrane of macrophages
from tumoral as well as juxtatumoral tissues, but not on the DC
populations analyzed. Next, we analyzed DC-SIGN mRNA
expression by RNA sequencing on each sorted population.
Among all the cell populations analyzed on tumor samples,
macrophages showed the highest DC-SIGN mRNA expression
(Figure 4(b)).
Fucosylated clusterin modulates the differentiation
profile of macrophages
Then, we analyzed whether fucosylated clusterin might be able
to switch the differentiation of macrophages into a functional
Figure 3. Single-cell analysis in breast cancer. Unsupervised principal component analysis (PCA) on the transcriptome of single-cell profiles (dots) colored by donor
(a), cell tumor state (b) and cell type (c) showing the separation between tumor and non-tumor cells. D. Clusterin expression is dominant tumor cells. Unsupervised
PCA of single-cell profiles with coloring of clusterin expression. E. Violin plots comparing clusterin expression based on cell types. Red lines show median expression
for each group. P-values computed are pairwise Wilcoxon rank sum test comparing clusterin expression in tumor cells and other groups (*** = p < .001). F. Co-
expression of Fucosyltransferases I, II, III and XI (FUT1, FUT2, FUT3 and FUT11) with clusterin in tumor cells is shown by PCA of single-cell profiles, showing clusterin
expre ssion (red), FUT expression (green) and co-expression (yellow) or non-expression (black) of clusterin and FUTs.
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profile able to promote tumor growth. To this aim we developed
an in vitro assay using fucosylated clusterin isolated from human
semen and humanmonocyte derivedmacrophages. As shown in
Figure 5(a,b), monocyte-derived macrophages express DC-
SIGN and bind fucosylated clusterin in a concentration-
dependent mode, reaching a plateau at concentrations of
20 µg/ml. Clusterin binding was prevented by the DC-SIGN
ligands mannan or α-L-fucose as well as by treatment of macro-
phages with a blocking mAb directed to DC-SIGN (Figure 5(c)).
Upon binding, fucosylated clusterin was rapidly internalized by
macrophages, as revealed by confocal microscopy (Figure 5(d)).
Having shown that fucosylated clusterin effectively interacts
with macrophages via DC-SIGN, we then analyzed its influence
on the phenotype and functional profile of macrophages. In
these experiments, monocytes were cultured for 5 days
with M-CSF, in the absence or presence of semen fucosylated
clusterin. Then, the cells were cultured for additional 24 hours
with or without LPS and the phenotype and the pattern of
cytokine production were analyzed. As shown in Figure 6(a),
fucosylated clusterin inhibited the classical clustering of LPS
stimulated macrophages. As shown in Figure 6(b), fucosylated
clusterin-treated macrophages failed to upregulate the expres-
sion of HLA-DR and CD86 induced by LPS but not the
expression of CD40, CD80 and PDL-1 (Figure 6(b)). Of note,
fucosylated clusterin significantly increased the production of
the angiogenic factors VEGF and IL-8, evaluated in both,
untreated and LPS-treated macrophages. Moreover, it signifi-
cantly increased the production of TNF-α by LPS-activated
macrophages, without modifying the production of IL-10 and
IL-6 (Figure 6(c)). IL-12 and IL-1 were undetectable in all the
conditions assessed (not shown). We conclude that fucosylated
clusterin inhibits the expression of cell surface molecules
involved in antigen presentation and promotes the differentia-
tion of macrophages into a pro-angiogenic profile.
Discussion
Since its discovery by Fritz and coworkers in 1983, clusterin has
shown to be involved in a variety of physiological and patholo-
gical processes such as cell death regulation, lipid transport,
sperm motility, unfolded protein clearance, Alzheimer’s disease
and cancer.1,2,29 An altered expression of clusterin in breast
cancer was first described by Redondo et al. in a large cohort
of cancer patients, showing a relationship between clusterin
overexpression and advanced disease.30 It is now accepted that
clusterin expression is associated with a poor prognosis and
disease recurrence in breast cancer as well as in many other
Figure 4. DC-SIGN expression by tumoral macrophages. a. Gating strategy used to identify the different populations of DCs and macrophages in tumoral and
juxtatumoral samples. CD45+, lineage negative (CD3, CD19, CD56) and HLA-DR+ cells were gated and four different populations of DCs were identified: CD11c-
CD123+ plasmacytoid pre-DCs (PDC), CD11c+ BDCA1+ CD14- DCs (BDCA1+), CD11c+ BDCA1- CD14- DCs (BDCA1-), and CD11c+ BDCA1+ CD14+ inflammatory DCs
(CD14+ DC). Macrophages were identified as CD11c+ BDCA1- CD14+ cells (MAC). b. The four populations of tumoral DCs and tumoral macrophages were sorted, and
the expression of DC-SIGN mRNA was determined by RNA-seq (n = 6–10). c. Flow cytometry analysis of cell surface DC-SIGN expression by the different populations
of DCs and macrophages from tumoral and juxtatumoral samples. A representative experiment (n = 5) is shown.
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Figure 5. Fucosylated clusterin interacts with macrophages. a. Expression of DC-SIGN by monocyte-derived macrophages. A representative experiment
(n = 7) is shown. b. Macrophages were incubated for 30 min at 4°C with different concentrations of fucosylated clusterin isolated from semen. Cells were
then washed, lysed and the binding of clusterin was revealed by ELISA. Results are expressed as the mean ± SD of 4 independent experiments.
c. Macrophages were incubated for 30 min at 4°C with fucosylated clusterin (10 µg/ml), in the absence or presence of a neutralizing mAb directed to DC-
SIGN (5 µg/ml), lactose (100 µg/ml), sucrose (100 µg/ml), mannan (1–100 µg/ml), or α-L-fucose (1–100 µg/ml). Cells were then washed, lysed and the
binding of clusterin was revealed by ELISA. Results are expressed as the mean ± SD of 3 experiments (**p < .01, *p < .05). d. Macrophages were
incubated for 15 min at 37°C with fucosylated clusterin (10 µg/ml) and clusterin endocytosis (green) was analyzed by confocal microscopy (n = 5,
bars:10µm).
Figure 6. Fucosylated clusterin promotes the differentiation of macrophages into a proangiogenic profile. a-c. Macrophages were differentiated from monocytes
cultured with M-CSF for 5 days, in the absence or presence of semen fucosylated clusterin. Then, cells were stimulated, or not, with LPS (10 ng/ml), and the pattern of
cell clustering (a), the expression of HLA-DR, CD86, PDL-1, CD40 and CD80 (b), and the production of VEGF, IL-8, TNF-α, IL-10, and IL-6 (c) were evaluated by optical
microscopy, flow cytometry or ELISA. Representative pictures (bars = 100µm) and histograms (n = 3–9) are shown in a and b. On b, the control condition mean
fluorescent intensities (MFI) of each independent experiment were normalized as 1. The mean of 5–9 independent experiments is shown. The mean of 5–7
independent experiments is shown in c (**p < .01, *p < .05).
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tumor types such as gastric, bladder, cervical, prostate, lung and
colorectal cancer.2,31–33 However, discrepant results have been
published in lung and prostate cancer regarding the value of
clusterin expression as a predictivemarker of a better response to
therapy.34–37 A possible explanation for these controversial
observations could be related to the existence of two different
clusterin isoforms, an anti-apoptotic form usually called secre-
tory clusterin and a nuclear form with pro-apoptotic activity.
These different isoforms might result from distinct transcripts
generated by alternative transcription initiation, possibly driven
by two distinct promoters.7
We have recently characterized a novel clusterin glycoform
present in semen that express abundant fucosylated LewisX and
LewisY motifs.10 Importantly, semen fucosylated clusterin, but
not serum sialylated clusterin, binds toDC-SIGN, a C-type lectin
receptor expressed by dendritic cells at the female genital
mucosa, inhibiting its interaction with HIV-1.10 In a similar
way than other seminal plasma glycoproteins, a multivalent
presentation of Lewisx/y sequences appears to be required for
the interaction between clusterin and DC-SIGN.17 Moreover, in
agreement with previous reports analyzing DC-SIGN interac-
tion with fucosylated ligands, we showed that fucosylated semen
clusterin promotes the acquisition of a tolerogenic profile by
conventional dendritic cells, suggesting a novel mechanism
through which semenmight promote tolerance tomale antigens,
thereby contributing to successful pregnancy.11 These results are
in line with a large body of evidence sustaining that glycan
functional groups are able to elicit tolerogenic effects that protect
human gametes and offspring in utero from immune rejection.
Interestingly, microorganisms and tumors seem to mimic this
strategy in order to evade the immune system.38,39
Our present results demonstrate the expression of fucosy-
lated clusterin in breast tumor samples and its ability to
interact with DC-SIGN. Fucosylated clusterin was absent or
diminished in juxtatumor tissues, suggesting that it might be
considered as a cancer associated glycoform. Indeed, aberrant
fucosylation of proteins is frequently found in cancer cells.14,15
In spite that we did not analyze whether breast cancer clus-
terin and seminal plasma clusterin bear identical fucosylated
motifs, we demonstrate that clusterin from both sources
express terminal fucosylated motifs able to bind DC-SIGN.
In fact, our observations suggest that these motifs are respon-
sible for the recognition of tumor clusterin by DC-SIGN.
However, due to the low amount of clusterin recovered
from tumor samples, we could not assay whether removal of
fucose motifs by fucosidases prevent the ability of tumor
clusterin to interact with DC-SIGN, as we have previously
shown for semen clusterin.10
We speculated that the ability of tumor fucosylated clusterin
to interact with DC-SIGN might induce the acquisition of
a tolerogenic profile by tumor DCs, promoting tumor escape
from the immune response. However, contrasting with obser-
vations made in other human tumors, we found that infiltrat-
ing DCs in breast cancer do not express DC-SIGN. By contrast,
intratumoral macrophages, which represent the predominant
myeloid cell population infiltrating breast tumors, as well as
juxtatumoral macrophages express DC-SIGN. Using semen
clusterin as a source of fucosylated clusterin and monocyte-
derived macrophages, we found that clusterin not only
inhibited the ability of LPS to stimulate the up-regulation of
T cell activating molecules by macrophages, such as MHC class
II and CD86, but also promoted the differentiation of macro-
phages into profile characterized by a high production of
VEGF, IL-8 and TNF-α. A weakness of our study is that we
were unable to isolate enough amounts of breast cancer clus-
terin to perform functional studies using tumor clusterin
instead of semen clusterin. Further studies are needed to char-
acterize the effect of tumor clusterin on the phenotype and
function of tumor infiltrating DC-SIGN+ macrophages.
Interestingly, the presence of fucosylated clusterin in tumors
does not appear to be restricted to breast cancer. In fact, we
also detected the expression of fucosylated clusterin in tumor
samples from patients with cervical cancer (unpublished
results), suggesting that it might represent a common marker
for different tumors. There is a large body of evidence indicat-
ing that lectin-glycan interactions modulate tumor angiogen-
esis, invasion and metastasis as well as tumor escape from the
immune response.13,40 Here we propose that tumor fucosylated
clusterin might be considered as a novel player in the tumor
microenvironment able to promote tumor progression by
interacting with tumor infiltrating DC-SIGN+ macrophages.
Materials and methods
Patients and samples
Breast tumor and juxtatumoral samples from previously
untreated cancer patients undergoing surgery were obtained
from the Institut Curie Hospital (Paris, France) in accordance
with Institut Curie ethical guidelines and the Declaration of
Helsinki. Patient characteristics are summarized in Table 1.
Samples were mechanically homogenized in a phosphate-
buffered saline (PBS) containing an EDTA-free protease inhi-
bitor cocktail (Roche) and stored at −80°C.
ELISA for the detection of fucosylated clusterin
An ELISA plate was treated overnight at 4°C with a PBS-
diluted IgG anti-clusterin mAb (R&D mAb 29372, 5µg/ml).
The plate was then blocked during 1 h using PBS containing
3% BSA (blocking buffer) (Sigma) at room temperature, and
washed 3 times using PBS containing 0.05% Tween. The
samples were diluted using blocking buffer, and incubated
for 2 h at room temperature in pre-treated plates. After
washing with PBS containing 0.05% Tween, the biotinylated
Ulex europaeus-1 (50µg/ml) or Lotus tetragonolobus (10µg/ml)
lectin diluted in blocking buffer were added, incubated for
30 min at room temperature and washed 3 times. The pre-
sence of fucosylated clusterin was revealed using streptavidin-
HRP and TMB ELISA substrate.
Total clusterin was detected by ELISA using a conventional
ELISA kit (Human Clusterin DuoSet ELISA, R&D Systems).
DC-SIGN binding
Western blot using DC-SIGN-huFc chimera (R&D 161-DC-050)
was carried out as described.10 Samples were analyzed by SDS-
PAGE (4–12% polyacrylamide gel under reducing conditions),
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transferred onto a nitrocellulose blot, treated with DC-SIGN-
huFc chimera (1 µg/ml in a buffer containing 20 mM Tris,
150 mM NaCl, 1 mM CaCl2, and 2 mM MgCl2 for 4 h at 4°C),
and stained with secondary antibodies. Alternatively, membranes
were treated with polyclonal goat IgG anti-clusterin (R&D
AF2937) and stained with secondary antibodies.
Binding of fucosylated clusterin to macrophages
Peripheral blood mononuclear cells were isolated from blood of
healthy donors by density gradient centrifugation using Ficoll-
Hypaque (GE Healthcare). Monocytes (>90% purity) were
obtained using CD14 microbeads (Miltenyi Biotec). To obtain
macrophages, monocytes were cultured for 5 days in RPMI
1640 medium containing 10% fetal bovine serum (Gibco) and
recombinant M-CSF (100 ng/ml)(Miltenyi Biotec).
Macrophages were incubated with fucosylated clusterin
(10 µg/ml), isolated from human seminal plasma as described
before,10 for 30 min at 4°C, extensively washed and lysed. The
amount of clusterin in cell lysates was measured by ELISA. In
some experiments, the binding of fucosylated clusterin to
macrophages was assessed in the presence of mannan
(Sigma), a blocking mAb directed to DC-SIGN (NIH AIDS
reagent program, cat no 6884, 5 µg/ml) or α-L-fucose (Sigma).
Confocal microscopy
Macrophages were placed on poly-L-lysine–coated glass cover-
slips (12mm) for 30min at room temperature. Clusterin binding
and endocytosis was carried out as follows: the cells were incu-
bated for 60 min at 4°C with fucosyalted clusterin (10 µg/ml).
The cells were washed and the coverslips were covered with
100 ml of complete medium and incubated at 37°C for 15 min
to allow endocytosis. The cells were washed with PBS and fixed
in 4% paraformaldehyde for 15 min on ice. Then, cells were
treated with 0.1 mM glycine in PBS and incubated with mAbs
directed to clusterin for 1 h, washed and stained with conjugated
secondary antibodies (Jackson Immuno Research, USA).
Coverslips were mounted on glass slides using Fluoromount
G. Immunofluorescence images were acquired with a Zeiss
LSM 800 confocal microscope. The row images are available
and can be requested to the corresponding author.
Fucosylated clusterin treatment of macrophages
Monocytes were isolated by positive selection using magnetic
beads (Miltenyi Biotec), and cultured in RPMI 1640 medium
containing 10% of inactivated-fetal bovine serum (Gibco) and
recombinant M-CSF (100 ng/ml) (Miltenyi Biotec), in the
presence or absence (control) of fucosylated clusterin
(20 µg/ml) isolated from human seminal plasma. After
5 days, the cells were stimulated with LPS (10 ng/ml) for
24h at 37ºC. Then, cells and supernatants were harvested
and analyzed by flow cytometry and ELISA, respectively.
Flow cytometry
Tumor samples were cut into small fragments, digested with
0.1 mg/ml of Liberase TL (Roche) in the presence of 0.1 mg/
mL DNase (Roche) for 20 min, before the addition of 10 mM
EDTA. Cells were then filtered through a 40 mm cell strainer
(BD Falcon) and washed. Staining was performed using the
following antibodies: anti-CD45 APC-Cy7 (BD), anti-CD14
Qdot 605 (Thermo), anti-CD3 Alexa700 (Biolegend), anti-CD
19 Alexa700 (Biolegend), anti-CD56 Alexa700 (Biolegend),
anti-HLA-DR BV711 (Biolegend), anti-CD11c PC5
(Beckman Coulter), anti-BDCA-1 PE (BD), anti-CD123
PCy7 (BD) and anti-C-SIGN FITC (BD). Cells were analyzed
by a LSRFORTESSA X-20 instrument (BD Biosciences). Data
was analyzed with FlowJo (Tree Star). The FACS files are
available and can be requested to the corresponding author.
RNA-seq data
We used the RNA-seq data obtained and previously published
by Michea et al.28 The data have been deposited in the NCBI
Sequence Read Archive (SRA) with the accession code
PRJNA380940.
Single cell analysis
Breast cancer SMART-Seq2 data was downloaded from the
NCBI Gene Expression Omnibus database (accession number :
GSE75688). SRA files were converted to FASTQ files with SRA
Toolkit (version 2.3.2-4). RNA AU: The funding information
provided has been checked against the Open Funder Registry
and we failed to find a match. Please check and resupply the
funding details. genome sequences (hg19) using the 2-pass mode
of STAR (version 2.5.3.a)41 (parameters: quantMode
GeneCounts, twopassMode Basic, alignSJDBoverhangMin 1,
bamRemoveDuplicatesType UniqueIdentical, winAnchor
MultimapNmax 1000, outFilterMultimapNmax 1000, outFilter
ScoreMinOverLread 0.33, outFilterMatchNminOverLread 0.33,
outFilterMismatchNoverLmax 0.04, outMultimapperOrder
Random, sjdbOverhang 99). Raw count tables were obtained
with Subread tool FeatureCounts (version 1.5.1)42 and formatted
as amatrix with a python script (version 3.6.2). Then, ENSEMBL
IDs in the matrix were changed to gene symbols using biotools
online converter (https://www.biotools.fr/human/ensembl_sym
bol_converter).
Metadata from the authors and the raw matrix were used to
create a SingleCellExperiment (version 1.4.1) R object. Quality
control, normalization and filtering steps were performed in
R environment (version 3.5.2). From the initial 563 cells pro-
files, 36 were removed because of missing information about
their cell type in the metadata. Cells were filtered by their
library size and their number of genes (respectively 7 and 2
cells were removed) using 3*Median Absolute Deviation
(MAD) method from Scater (version 1.10.1).43 Counts were
normalized using deconvolution strategy, which divide the
counts for each cell by the size factor for that cell. This was
performed using Scater (version 1.10.1) which perform the
normalization and Scran (version 1.10.2)44 which compute
size factors. Only genes with at least 1 count by cell were
kept considering their size factors. Finally, a PCA on quality
control metrics was performed to remove outlier cells profiles
that have substantially different quality control metrics from
the others (8 removed) using Scater (version 1.10.1).
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Expression scaling, Principal Component Analysis and data
visualization were done using R packages Seurat 3.045 on the
510 remaining single-cell profiles.
Statistics
Statistical comparisons were performed by using paired
Student’s t-test or ANOVA. The p values <.001(***), <0.01
(**) and <0.05 (*) were considered statistically significant. The
single cell analysis was performed using pairwise Wilcoxon
rank sum test.
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